EFFICACY AND SAFETY OF DRUGS USED FOR TREATMENT OF NAUSEA AND VOMITING IN PREGNANT WOMEN


Cite item

Full Text

Abstract

The article discusses various methods of treatment of nausea and vomiting in pregnancy (non-pharmacological and pharmacological). Among the pharmacological methods, including for self-treatment, plant preparation (ginger, peppermint and raspberry leaves) are widespread. Medications used for treatment of these symptoms in pregnant women include pyridoxine, H1-blockers, dopamine and serotonin receptors antagonists, and glucocorticoids. However, despite the large selection of antiemetics, evidence-based data for their safety and efficacy in pregnant women are limited. Further studies on the effectiveness and safety of drugs used for the treatment of nausea and vomiting in pregnant women are necessary.

References

  1. King TL, Murphy PA. Evidence-Based Approaches to Managing Nausea and Vomiting in Early Pregnancy J Midwifery Womens Health 2009;54(6):430-44.
  2. Magee LA, Mazzotta P, Koren G. Evidence-based view of safety and effectiveness of pharmacologic therapy for nausea and vomiting of pregnancy (NVP). Am J Obstet Gynecol 2002;186:256-61.
  3. Hollyer T, Boon H, Georgousis A, et al. The use of CAM by women suffering from nausea and vomiting during pregnancy. BMC Complement Altern Med 2002;2:5.
  4. Betz O, Kranke P, Geldner G, et al. Is ginger a clinically relevant antiemetic? A systematic review of randomized controlled trials. Forsch Komplementarmed Klass Naturheilkd 2005;12(1):14-23.
  5. Matthews A, Dowswell T, Haas DM, et al. Interventions for nausea and vomiting in early pregnancy. Cochrane Database Syst Rev 2010;9:CD007575.
  6. White B. Ginger: An Overview Am Fam Physician 2007;75(11):1689-91.
  7. Hoffman T. Ginger: an ancient remedy and modern miracle drug. Hawaii Med J 2007;66(12):326-27.
  8. Sahakian V, Rouse D, Sipes S, et al. Vitamin B6 is effective therapy for nausea and vomiting of pregnancy: A randomized, double-blind placebo-controlled study. Obstet Gynecol 1991;78:33-6.
  9. Vutyavanich T, Wongtra-ngan S, Ruangsri R. Pyridoxine for nausea and vomiting of pregnancy: A randomized, double-blind, placebo-controlled trial. Am J Obstet Gynecol 1995;173:881-4.
  10. Tan PC, Yow CM, Omar SZ. A placebo-controlled trial of oral pyridoxine in hyperemesis gravidarum. Gynecol Obstet Invest 2009;67(3):151-57.
  11. Office of Dietary Supplements, National Institutes of Health Web site. Dietary supplement fact sheet: Vitamin B6. Available from: http://ods.od.nih.gov/factsheets/vitaminb6.asp#h3;
  12. Schaumburg H, Kaplan J, Windebank A, et al. Sensory neuropathy from pyridoxine abuse. A new megavitamin syndrome. N Engl J Med 1983;309:445-48.
  13. Seto A, Einarson T, Koren G. Pregnancy outcome following first trimester exposure to antihistamines: Meta-analysis. Am J Perinatol 1997;14:119-24.
  14. Gilboa SM, Strickland MJ, Olshan AF, et al. Use of antihistamine medications during early pregnancy and isolated major malformations. Birth Defects Res A Clin Mol Teratol 2009;85(2):137-50.
  15. Kargas GA, Kargas SA, Bruyere HJ Jr, et al. Perinatal mortality due to interaction of diphenhydramine and temazepam. N Engl J Med 1985;313:1417-18.
  16. Rumeau-Rouquette C, Goujard J, Huel G. Possible teratogenic effect of phenothiazines in human beings. Teratology 1976;15:57-64.
  17. Slone D, Siskind V, Heinonen OP, et al. Antenatal exposure to the phenothiazines in relation to congenital malformations, perinatal mortality rate, birth weight, and intelligence quotient score. Am J Obstet Gynecol 1977;128:486-88.
  18. Einarson A, Boskovic R. Use and safety of antipsychotic drugs during pregnancy. J Psychiatr Pract 2009;15(3):183-92.
  19. Gentile S. Antipsychotic therapy during early and late pregnancy. A systematic review. Schizophr Bull 2010;36(3):518-44.
  20. Bennedsen BE. () Adverse pregnancy outcome in schizophrenic women: occurrence and risk factors. Schizophrenia Research 1998;33:1-26.
  21. Sacker A, Done DJ, Crow TJ. Obstetric complications in children born to parents with schizophrenia: a meta-analysis of case control studies. Psychological Medicine 1996;26:279-87.
  22. Altshuler LL, Cohen L, Szuba MP, et al. Pharmacologic management of psychiatric illness during pregnancy: dilemmas and guidelines. Am J Psychiatry 1996;153:592-606.
  23. Sobel DE. Fetal damage due to ECT, insulin, coma, chlorpromazine or reserpine. Arch Gen Psychiatry 1960;2:606-11.
  24. Levy W, Winniewski K. Chlorpromazine causing extrapyramidal dysfunction in newborn infant of psychotic mother. NY State J Med 1974;74:684-85.
  25. Sexson WR, Barak Y. Withdrawal emergent syndrome in an infant associated with maternal haloperidol therapy. J Perinatol 1989;9:170-72.
  26. Ayd F. Is psychiatry in a crisis because of the complications of the psychopharmaceuticals? Dis Nerv Syst 1968;29:23-5.
  27. Hauser LA. Pregnancy and psychotropic drugs. Hospital and Community Psychiatry. 1985;36:817-18.
  28. Matok I, Gorodischer R, Koren G, et al. The safety of metoclopramide use in the first trimester of pregnancy. N Engl J Med 2009;360:25-8.
  29. Haddad PM, Anderson IM. Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. Drugs 2002;62(11):1649-71.
  30. American College of Obstetricians and Gynecologists (ACOG). ACOG Practice Bulletin: Nausea and vomiting of pregnancy. Obstet Gynecol 2004;103:803-14.
  31. Van Waes A, Van de Velde E. Safety evaluation of haloperidol in the treatment of hyperemesis gravidarum. J Clin Pharmacol 1969;9:224-27.
  32. Diav-Citrin O, Shechtman S, Ornoy S, et al. Safety of haloperidol and penfluridol in pregnancy: a multicenter, prospective, controlled study. J Clin Psychiatry 2005;66(3):317-22.
  33. Sullivan CA, Johnson CA, Roach H, et al. A pilot study of intravenous ondansetron for hyperemesis gravidarum. Am J Obstet Gynecol 1996;174:1565-68.
  34. Ye JH, Ponnudurai R, Schaefer R. Ondansetron: a selective 5-HT(3) receptor antagonist and its applications in CNS-related disorders. CNS Drug Rev 2001;7(2):199-213.
  35. Hesketh PJ. Comparative review of 5-HT3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting. Cancer Invest 2000;18(2):163-73.
  36. Navari RM, Koeller JM. Electrocardiographic and cardiovascular effects of the 5-hydroxytryptamine 3 receptor antagonists. Ann Pharmacother 2003;37(9):1276-86.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2011 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies